Payment overview · 2025
General Payments
$1,080.47
58 reported records · 13 companies
Healthcare provider profile · identity verified
Lora A Pomykala, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1275534752
Verified facts
What the public records show
CMS Open Payments records show Lora A Pomykala, MD received $1,080.47 in general payments during 2025 across 58 reported records.
Novo Nordisk Inc accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $454.02 | 42.0% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.21 | 14.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.23 | 8.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.85 | 7.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.07 | 6.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.93 | 5.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.60 | 4.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.98 | 2.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.20 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.10 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.47 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.32 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,080.47 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $261.96 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $149.42 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $145.03 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.46 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.47 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.85 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.85 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.07 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.93 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.62 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $24.28 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
116 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
106 | 106 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 32 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 719 | 201 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 691 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 576 | 169 |
| Losartan Potassium | Losartan Potassium | 397 | 126 |
| Omeprazole | Omeprazole | 333 | 97 |
| Montelukast Sodium | Montelukast Sodium | 327 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 96 |
| Meloxicam | Meloxicam | 315 | 94 |
| Alprazolam | Alprazolam | 313 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 85 |
| Zolpidem Tartrate | Zolpidem Tartrate | 274 | 56 |
| Lisinopril | Lisinopril | 273 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 71 |
| Metformin Hcl | Metformin Hcl | 244 | 78 |
| Trazodone Hcl | Trazodone Hcl | 239 | 75 |
| Famotidine | Famotidine | 208 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 70 |
| Gabapentin | Gabapentin | 186 | 53 |
| Valsartan | Valsartan | 185 | 57 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 176 | 57 |
| Ozempic | Semaglutide | 167 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 45 |
| Metformin Hcl Er | Metformin Hcl | 152 | 47 |
| Ezetimibe | Ezetimibe | 150 | 51 |
| Simvastatin | Simvastatin | 149 | 39 |
| Sertraline Hcl | Sertraline Hcl | 141 | 43 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 132 | 36 |
| Carvedilol | Carvedilol | 125 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 35 |
| Synthroid | Levothyroxine Sodium | 116 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 106 | 106 |
| Risedronate Sodium | Risedronate Sodium | 106 | 28 |
| Allopurinol | Allopurinol | 104 | 26 |
| Furosemide | Furosemide | 104 | 43 |
| Alendronate Sodium | Alendronate Sodium | 103 | 27 |
| Irbesartan | Irbesartan | 99 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 35 |
| Lorazepam | Lorazepam | 92 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 89 | 27 |
| Potassium Chloride | Potassium Chloride | 88 | 28 |
| Bupropion Xl | Bupropion Hcl | 87 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 21 |
| Glimepiride | Glimepiride | 81 | 25 |
| Spironolactone | Spironolactone | 81 | 23 |
| Tramadol Hcl | Tramadol Hcl | 81 | 16 |
| Amoxicillin | Amoxicillin | 80 | 69 |
| Cefdinir | Cefdinir | 77 | 65 |
| Eliquis | Apixaban | 75 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 15 |
| Jardiance | Empagliflozin | 73 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 58 |
| Trulicity | Dulaglutide | 71 | 14 |
| Mounjaro | Tirzepatide | 70 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Atenolol | Atenolol | 67 | 17 |
| Donepezil Hcl | Donepezil Hcl | 63 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 16 |
| Celecoxib | Celecoxib | 56 | 18 |
| Clonazepam | Clonazepam | 56 | 12 |
| Fenofibrate | Fenofibrate | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 22 |
| Methylprednisolone | Methylprednisolone | 52 | 45 |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 47 | 47 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 13 |
| Estradiol | Estradiol | 45 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 14 |
| Telmisartan | Telmisartan | 44 | 12 |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Diazepam | Diazepam | 38 | suppressed |
| Gemtesa | Vibegron | 38 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 19 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 17 |
| Propranolol Hcl | Propranolol Hcl | 29 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 22 |
| Topiramate | Topiramate | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Fluconazole | Fluconazole | 24 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ramipril | Ramipril | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,080.47 · 58 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error